Stifel Maintains Buy on Beam Therapeutics, Raises Price Target to $69
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett maintains a Buy rating on Beam Therapeutics and raises the price target from $66 to $69.
September 11, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Benjamin Burnett has reiterated a Buy rating for Beam Therapeutics and increased the price target from $66 to $69, indicating confidence in the company's future performance.
The increase in price target from $66 to $69 by Stifel suggests a positive outlook for Beam Therapeutics, likely boosting investor confidence and potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100